Table 35aVesco et al35: Sensitivity Analysis Varying Estimates of Screening Adherence*

StrategyColposcopiesIncremental ColposcopiesLife Years (LYs)Incremental LYsICLY
No intervention069016.30
Cytology and HPV, q5, Age 3025425469152.04135.742
Cytology and HPV, q3, Age 3036711269183.3931.344
Cytology and HPV, q2, Age 3052616069203.8520.478
Cytology and HPV, q1, Age 3077024369225.9422.0911
*

Results are presented as expected colposcopies per 1,000 women, incremental colposcopies, life-years, incremental life-years, and incremental colposcopies per life-year (ICLY) for strategies identified as efficient. Age at which to begin screening is fixed at age 21 years. For the combined cytology and HPV strategies, cytology-based screening only is assumed prior to age 30 years, with a repeat cytology test for ASC-US results. The strategy of cytology and HPV testing begins at age 30 years. Screening intervals of every 1 (q1), 2 (q2), 3 (q3), and 5 (q5) years are compared.

From: Results

Cover of Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force
Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force [Internet].
Evidence Syntheses, No. 86s.
Kulasingam SL, Havrilesky L, Ghebre R, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.